Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

NCT03525925 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Solid Neoplasm

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab

Sponsor

Ohio State University Comprehensive Cancer Center